Preparing for the 2021-2022 Flu Season

Experts say the 2021-2022 Flu and Respiratory season will be unpredictable.

AMI Partners with LifeSign To Provide the Status COVID-19/Flu A&B Test for Upcoming Response Season

Under the LifeSign distributor list, $Chembio Diagnostics(CEMI)$currently one of the distributors for the Status ™ COVID-19/FLU Product

The only FDA EUA visual read rapid test for Simultaneous detection and differential diagnosis of SARS-CoV-2, Influenza Type A & Influenza Type B Antigen in nasopharyngeal swab specimens.

Performance Characters

COVID-19: Sensitivity 93.9%; Specification 100%

Flu A: Sensitivity 91.4%; Speciality 95.7%

Flu B: Sensitivity 87.6%; Speciality 95.9%

Efficient

3 tests in 1 consolidates and speeds workflow

Fast results in only 15 minutes

Easy to run with no pipetting and premeasured buffer

Room temperature storage

Convenient

Generate revenue by processing results in-house

Visual read removes capital equipment analyzer costs

Collect 1 sample for both COVID-19, Flu A and Flu B

Simplified "Go Live" with Chembio's enhanced on site training program

Stay tuned for tomorrow webinar on 18th August 2021 @ 2: 00pm EST with Dr. Lauren Meyers and Dr. Aubree Gordon to hear more on this topic. 💻

Do not miss this webinar by Chembio Diagnostics & NACCHO (National Association of County and City Health Offices) 📈

Dr. Meyers received her BA in mathematics and philosophy at Harvard University and PhD in biology at Stanford University. She was named as one of the top 100 global innovators under 35 by the MIT Technology Review in 2004 and received the Joseph Lieberman Award for Significant Contributions to Science in 2017.

Dr. Aubree Gordon is a world leader in influenza epidemiology, focused on the dynamIcs of virtual transmission and development of society to response viruses.